Rituximab
- Generic Name
- Rituximab
- Brand Names
- MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 174722-31-7
- Unique Ingredient Identifier
- 4F4X42SYQ6
- Background
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...
- Indication
Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...
- Associated Conditions
- Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
- Associated Therapies
- -
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- University Hospital, Tours
- Target Recruit Count
- 102
- Registration Number
- NCT06549231
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06541665
- Locations
- 🇯🇵
Kindai University Hospital, Osakasayama-shi, Osaka, Japan
🇯🇵Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵National Hospital Organization Disaster Medical Center, Midori-cho, Tokyo, Japan
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients With Treatment-naive Non-GCB DLBCL
- Conditions
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Target Recruit Count
- 30
- Registration Number
- NCT06530511
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, China
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 50
- Registration Number
- NCT06530004
- Locations
- 🇨🇳
First affiliated hospital of xiamen university, Xiamen, Fujian, China
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06522386
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 244
- Registration Number
- NCT06521255
- Locations
- 🇨🇳
Xinjiang Medical University Affiliated Cancer Hospital, Urumqi, China
🇨🇳Henan Cancer Hospital, Zhengzhou, China
🇨🇳Beijing Hospital, Beijing, China
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Target Recruit Count
- 528
- Registration Number
- NCT06516978
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Gottfried von Keudell, MD PhD
- Target Recruit Count
- 33
- Registration Number
- NCT06510309
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 360
- Registration Number
- NCT06508658
- Locations
- 🇦🇺
Toowoomba Hospital /ID# 263243, Toowoomba, Queensland, Australia
🇧🇪Universitair Ziekenhuis Brussel /ID# 242574, Jette, Bruxelles-Capitale, Belgium
🇧🇪AZ-Delta /ID# 264740, Roeselare, West-Vlaanderen, Belgium
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT06496308
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.